MCID: HYP025
MIFTS: 47

Hyperphosphatemia malady

Category: Metabolic diseases

Aliases & Classifications for Hyperphosphatemia

About this section

Aliases & Descriptions for Hyperphosphatemia:

Name: Hyperphosphatemia 11 27 50 39 13 68

Classifications:



External Ids:

Disease Ontology11 DOID:0050459
MeSH39 D054559
SNOMED-CT62 20165001
NCIt45 C113750

Summaries for Hyperphosphatemia

About this section
Wikipedia:71 Hyperphosphatemia is an electrolyte disturbance in which there is an abnormally elevated level of... more...

MalaCards based summary: Hyperphosphatemia is related to pseudohypoparathyroidism, type ib and pseudohypoparathyroidism ic. An important gene associated with Hyperphosphatemia is FGF23 (Fibroblast Growth Factor 23), and among its related pathways are Osteoblast Signaling and Vitamin D Metabolism. Affiliated tissues include kidney, bone and smooth muscle, and related mouse phenotypes are digestive/alimentary and craniofacial.

Related Diseases for Hyperphosphatemia

About this section

Diseases related to Hyperphosphatemia via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50)    (show all 97)
idRelated DiseaseScoreTop Affiliating Genes
1pseudohypoparathyroidism, type ib31.4GNAS, PTH, STX16
2pseudohypoparathyroidism ic31.2GNAS, PTH, STX16
3calcinosis30.3FGF23, KL, PTH
4tumoral calcinosis, hyperphosphatemic, familial11.9
5hypoparathyroidism, familial isolated10.9
6hypoparathyroidism-retardation-dysmorphism syndrome10.7
7hypocalcemia, autosomal dominant10.7
8pseudohypoparathyroidism ia10.7
9kidney disease10.3
10lymphangioleiomyomatosis10.2FGF23, SLC34A1
11peroxisome biogenesis disorder 2b10.2FGF23, GALNT3
12oligospermia10.2FGF23, KL
13y chromosome detection10.2PTH, VDR
14hyperostosis10.2
15opthalmoplegia mental retardation lingua scrotalis10.2FGF23, PTH
16cole disease10.2GALNT3, MGP
17peritonitis10.1
18prostate cancer, hereditary, x-linked 210.1FGF23, SLC34A1, VDR
19maroteaux stanescu cousin syndrome10.1FGF23, RUNX2
20inclusion-cell disease10.1GNAS, STX16
21donnai-barrow syndrome10.1FGF23, GALNT3, KL
22joubert syndrome 910.1FGF23, PTH, SLC34A1
23feigenbaum bergeron richardson syndrome10.1FGF23, GALNT3, KL
24hyperparathyroidism10.1
25opportunistic bacterial infectious disease10.1FGF23, PTH, SLC34A1
26osseous heteroplasia, progressive10.1FGF23, GNAS
27acth-independent macronodular adrenal hyperplasia10.1GNAS, RUNX2
28prediabetes syndrome10.1FGF23, PTH
29leukemia10.1
30macrocephaly/megalencephaly syndrome, autosomal recessive10.1GCM2, PTH
31chronic myocardial ischemia10.1FGF23, PTH, VDR
32acrorenal syndrome10.1PTH, RUNX2, VDR
33dysbaric osteonecrosis10.1PTH, RUNX2, VDR
34osteochondrodysplasia10.0KL, PTH, VDR
35obesity, severe bmiq910.0GNAS, PTH, STX16
36intracranial thrombosis10.0GNAS, PTH, STX16
37esophageal leukoplakia10.0GNAS, PTH, STX16
38prune belly syndome10.0GCM2, PTH
39deafness, nonsyndromic, modifier 110.0CASR, VDR
40striatonigral degeneration10.0CASR, PTH
41orbit lymphoma10.0FGF23, GALNT3, KL, PTH
42ischemic bone disease10.0FGF23, PTH, RUNX2, VDR
43lymphoblastic leukemia10.0
44familial tumoral calcinosis10.0
45interstitial nephritis10.0PTH, SLC34A1
46familial chronic myelocytic leukemia-like syndrome9.9CASR, PTH
47childhood absence epilepsy9.9FGF23, GALNT3, KL, MGP
48multiple myeloma9.9
49lactic acidosis9.9
50uremia9.9

Graphical network of the top 20 diseases related to Hyperphosphatemia:



Diseases related to hyperphosphatemia

Symptoms & Phenotypes for Hyperphosphatemia

About this section

MGI Mouse Phenotypes related to Hyperphosphatemia according to GeneCards Suite gene sharing:

41 (show all 14)
idDescriptionMGI Source AccessionScoreTop Affiliating Genes
1MP:00053819.2CASR, FGF23, GALNT3, KL, RUNX2, VDR
2MP:00053829.0GALNT3, GCM2, GNAS, PTH, RUNX2, VDR
3MP:00107718.7CASR, FGF23, GALNT3, GNAS, KL, RUNX2
4MP:00053718.5FGF23, GALNT3, GNAS, KL, PTH, RUNX2
5MP:00053698.3CASR, GNAS, KL, MGP, RUNX2, SLC34A1
6MP:00053978.3CASR, FGF23, GALNT3, GNAS, KL, PTH
7MP:00053878.2CASR, FGF23, GALNT3, GNAS, KL, PTH
8MP:00053858.1FGF23, GALNT3, GNAS, KL, MGP, PTH
9MP:00053797.8CASR, FGF23, GALNT3, GCM2, GNAS, KL
10MP:00053677.6CASR, FGF23, GALNT3, GCM2, GNAS, KL
11MP:00053787.4CASR, FGF23, GALNT3, GNAS, KL, MGP
12MP:00107687.1CASR, FGF23, GCM2, GNAS, KL, MGP
13MP:00053766.9CASR, FGF23, GALNT3, GCM2, GNAS, KL
14MP:00053906.1CASR, FGF23, GALNT3, GCM2, GNAS, KL

Drugs & Therapeutics for Hyperphosphatemia

About this section

Drugs for Hyperphosphatemia (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50)    (show all 86)
idNameStatusPhaseClinical TrialsCas NumberPubChem Id
1
SevelamerapprovedPhase 4, Phase 3, Phase 2, Phase 17452757-95-6, 152751-57-03085017
Synonyms:
Sevelamer
 
Sevelamero
Sevelamerum
Sévélamer
2
Calcium acetateapprovedPhase 4, Phase 3, Phase 12062-54-4
Synonyms:
Acetate OF lime
Brown acetate of lime
Ca(oac)2
 
Gray acetate of lime
Lime acetate
Lime pyrolignite
calcium ethanoate
calcium(II) acetate
3
AlendronateapprovedPhase 4162121268-17-5, 66376-36-12088
Synonyms:
(4-Amino-1-hydroxybutylidene)bisphosphonic acid
(4-Amino-1-hydroxybutylidene)diphosphonic acid
(4-amino-1-hydroxy-1-phosphonobutyl)phosphonic acid
(4-amino-1-hydroxybutane-1,1-diyl)bis(phosphonic acid)
(4-amino-1-hydroxybutylidene)bisphosphonic acid
121268-17-5 (mono-hydrochloride salt, trihydrate)
1yhm
4-Amino-1-hydroxybutane-1,1-diphosphonate
4-Amino-1-hydroxybutane-1,1-diphosphonic Acid
4-Amino-1-hydroxybutylidene-1,1-bis(phosphonic acid)
4-Amino-1-hydroxybutylidene-1,1-bisphosphonate
4-amino-1-hydroxybutane-1,1-diphosphonic acid
66376-36-1
ABDP
AC1L1CW3
AKOS001015793
ALENDRONATE SODIUM
ALENDRONIC ACID
Acide Alendronique
Acide Alendronique [INN-French]
Acide alendronique
Acide alendronique [INN-French]
Acido Alendronico
Acido Alendronico [INN-Spanish]
Acido alendronico
Acido alendronico [INN-Spanish]
Acidum Alendronicum
Acidum Alendronicum [INN-Latin]
Acidum alendronicum
Acidum alendronicum [INN-Latin]
Adronat
 
Alendronate
Alendronate Sodium
Alendronate sodium hydrate
Alendronic acid
Alendronic acid (INN)
Alendronic acid [INN:BAN]
Alendros
Arendal
BIDD:GT0180
C07752
CHEBI:2567
CHEMBL870
CID2088
D07119
DB00630
Fosamax
Fosamax Plus D
HSCI1_000337
LS-106421
MK 217
MK-217
MolPort-000-421-410
NCGC00096054-01
NCGC00096054-03
NCGC00096054-04
Onclast
Oprea1_422906
Phosphonic acid, (4-amino-1-hydroxybutylidene)bis
SPECTRUM1505166
ST50036159
UNII-X1J18R4W8P
alendronate
bisphosphonate, 65
4
IronapprovedPhase 4, Phase 3, Phase 211657439-89-623925
Synonyms:
02583_FLUKA
12310_ALDRICH
12310_RIEDEL
129048-51-7
14067-02-8
161135-39-3
190454-13-8
195161-83-2
199281-22-6
209309_ALDRICH
209309_SIAL
255637_ALDRICH
266213_ALDRICH
266256_ALDRICH
267945_ALDRICH
267953_ALDRICH
26Fe
338141_ALDRICH
356808_ALDRICH
356824_ALDRICH
356832_ALDRICH
39344-71-3
3ZhP
413054_ALDRICH
443783-52-6
44890_ALDRICH
44890_FLUKA
675141-17-0
70884-35-4
73135-38-3
7439-89-6
8011-79-8
8053-60-9
AC1L2N38
ATW 230
ATW 432
Ancor B
Ancor en 80/150
Armco iron
Atomel 28
Atomel 300M200
Atomel 500M
Atomel 95
Atomiron 44MR
Atomiron 5M
Atomiron AFP 25
Atomiron AFP 5
C00023
C3518_SIAL
C3518_SIGMA
CCRIS 1580
CHEBI:18248
CID23925
Carbonyl iron
Copy Powder CS 105-175
D007501
DB01592
DSP 1000
DSP 128B
DSP 135
DSP 135C
DSP 138
Diseases (animal), iron overload
Diseases, iron overload
EF 1000
EF 250
EFV 200/300
EFV 250
EFV 250/400
EINECS 231-096-4
 
Ed-In-Sol
Eisen
Electrolytic iron
F 60 (metal)
FE
FT 3 (element)
Fe
Fe-40
Fe1+
Feronate
Ferretts
Ferro-Caps
Ferro-Time
Ferrousal
Ferrovac E
Ferrum
Ferrum metallicum
GS 6
HF 2 (element)
HL (iron)
HQ (metal)
HS (iron)
HS 4849
HSDB 604
Hemocyte
Hierro
Hoeganaes ATW 230
Hoeganaes EH
IRMM524A_FLUKA
IRMM524B_FLUKA
IRON
Iron (Fe)
Iron (Fe1+)
Iron ion (Fe+)
Iron ion(1+)
Iron monocation
Iron powder
Iron standard for AAS
Iron(1+)
Iron(1+) ion
Iron(III) nitrate solution
Iron, carbonyl
Iron, electrolytic
Iron, elemental
Iron, ion (Fe1+)
Iron, ion (Fe1+) (8CI,9CI)
Iron, reduced
LOHA
LS-3196
MolPort-003-925-001
NC 100
PZh-1M3
PZh-2
PZh1M1
PZh2M
PZh2M1
PZh2M2
PZh3
PZh3M
PZh4M
PZhO
Reduced iron
Remko
SUY-B 2
Siderol
UNII-E1UOL152H7
Vitedyn-Slo
Yieronia
fer
ferrous iron
hierro
5
Calcium carbonateapprovedPhase 4, Phase 3, Phase 2215471-34-1
Synonyms:
CaCO3
Calcium carbonate
Calcium carbonate (1:1)
Calciumcarbonat
Carbonate de calcium
 
Carbonato de calcio
Carbonic acid calcium salt (1:1)
E 170
Kalziumkarbonat
Kohlensaurer kalk
Precipitated calcium carbonate
6
Nitroglycerinapproved, investigationalPhase 415655-63-04510
Synonyms:
1,2,3-Propanetrioltrinitrate
1,2,3-Propanetriyl nitrate
100292-13-5
105469-31-6
55-63-0
80066-48-4
8013-23-8
9010-02-0
AC1L1IBV
Adesitrin
Aldonitrin
Angibid
Angiolingual
Angiplex
Anglix
Angonist
Angorin
Anogesic
Aquo-Trimitrosan
BIDD:GT0142
BRN 1802063
Blasting gelatin
Blasting oil
Buccal
Buccard
C07455
C3H5N3O9
CCRIS 4089
CHEBI:28787
CHEMBL730
CID4510
CPD-143
Cardabid
Cardamist
Cardinit
Cardiodisco
Cellegesic
Chitamite
Colenitral
Cordipatch
Corditrine
Coro-Nitro
D00515
D005996
DB00727
Dauxona
Deponit
Deponit 5
Deponit TTS 10
Deponit TTS 5
Deponit-5
Diafusor
Discotrine
Dynamite
EINECS 200-240-8
Epinitril
GTN
GTN-Pohl
Gepan Nitroglicerin
Gilucor nitro
Gilustenon
Glonoin
Glycerin trinitrate
Glycerine trinitrate
Glycerintrinitrate
Glycerol trinitrate
Glycerol, nitric acid triester
Glyceroli trinitratis
Glyceroltrinitraat
Glyceroltrinitrat
Glyceryl
Glyceryl nitrate
Glyceryl trinitrate
Glycerylnitrat
Glytrin
HMS2094M15
HSDB 30
Herwicard
Herzer
IMX-150
Klavikordal
LS-7741
Lenitral
Lentonitrina
MED-2002
MQX-503
Mi-Trates
Millisrol
Minitram
Minitran
Minitran (TN)
Minitro
Mionitrat
Myocon
Myoglycerin
Myovin
NG
NITRO IV
NK-843
NTG
Natispray
Neos nitro OPT
Niglin
Niglycon
Niong
Niong Retard
Nirmin
Nit-Ret
Nitora
Nitradisc
Nitradisc Pad
Nitradisc TTS
Nitrangin
Nitrek
Nitriderm
Nitriderm TTS
Nitrine-TDC
Nitro Bid
Nitro Dur
Nitro Dur TTS
Nitro Mack Retard
Nitro Retard
Nitro Rorer
Nitro-Bid
Nitro-Dur 10
Nitro-Dur 5
Nitro-Gesanit Retard
Nitro-M-Bid
Nitro-Mack Retard
Nitro-Par
Nitro-Pflaster
Nitro-Span
Nitro-Time
Nitro-bid (TN)
Nitro-dur
Nitro-dur (TN)
Nitro-lent
NitroBid
NitroCor
 
NitroDur
NitroMist
NitroQuick
NitroQuik
Nitroard
Nitrobaat
Nitrobid Oint
Nitrobukal
Nitrocap
NitrocapT.D
NitrocapT.D.
Nitrocard
Nitrocerin
Nitrocine
Nitrocine 5
Nitroclyn
Nitrocontin
Nitrocontin Continus
Nitrocot
Nitroderm
Nitroderm TTS
Nitroderm TTS Ext
Nitroderm TTS-5
Nitrodisc
Nitrodyl
Nitrodyl TTS
Nitrogard
Nitrogard-SR
Nitroglicerina
Nitrogliceryna
Nitroglin
Nitroglycerin
Nitroglycerin (NG)
Nitroglycerin ointment
Nitroglycerin-ACC
Nitroglycerine
Nitroglycerol
Nitroglyn
Nitroject
Nitrol Ointment
Nitrolan
Nitroletten
Nitrolin
Nitrolingual
Nitrolingual Spray
Nitrolowe
Nitromack Retard
Nitromed
Nitromel
Nitromex
Nitromint
Nitromint Aerosol
Nitromint Retard
Nitromist
Nitromist (TN)
Nitronal Aqueous
Nitronet
Nitrong
Nitrong Retard
Nitrong parenteral
Nitrong-SR
Nitropatch
Nitropen
Nitropercuten
Nitroperlinit
Nitroplast
Nitroprol
Nitropront
Nitroprontan
Nitrorectal
Nitroretard
Nitrorex
Nitrospan
Nitrostabilin
Nitrostat
Nitrovis
Nitrozell retard
Nysconitrine
Percutol
Percutol Oint
Percutol Oint.
Perganit
Perglottal
Perlinganit
Plastranit
Polnitrin
Propane-1,2,3-triyl trinitrate
RCRA waste no. P081
Ratiopharm
Rectogesic
SDM No. 17
SK-106N
SK-866
SK-878
Soup
Spirit of glonoin
Susadrin
Suscard
Sustac
Sustak
Sustonit
TNG
Temponitrin
Top-Nitro
Transderm Nitro
Transderm nitro
Transderm-N TTS
Transderm-Nitro TTS
Transderm-nitro
Transderm-nitro (TN)
Transiderm-nitro
Tridil
Tridil sublin
Trinalgon
Trinipatch
Triniplas
Trinitrate, Glyceryl
Trinitrin
Trinitrin Tablets
Trinitrina Erba
Trinitrine
Trinitroglycerin
Trinitroglycerol
Trinitrol
Trinitrolong
Trinitron
Trinitrosan
Turicard
UN0143
UN0144
UN1204
UN3064
UN3319
UNII-G59M7S0WS3
Vascana
Vasoglyn
Vasolator
Vernies
Willong
c0061
nitroglycerin
7
Ergocalciferolapproved, nutraceuticalPhase 4, Phase 2128150-14-65280793
Synonyms:
'Ergosterol irradiated'
(+)-Vitamin D2
(3-beta,5Z,7E,22E)-9,10-Secoergosta-5,7,10,(19),22-tetraen-3-ol
(3S,5Z,7E,14xi,17alpha,22E)-9,10-secoergosta-5,7,10,22-tetraen-3-ol
(3S,5Z,7E,22E)-9,10-secoergosta-5,7,10(19),22-tetraen-3-ol
(3S,5Z,7E,22E)-9,10-secoergosta-5,7,10,22-tetraen-3-ol
(3beta,5Z,7E,22E)-9,10-secoergosta-5,7,10(19),22-tetraen-3-ol
(3beta,5Z,7e,22e)-9,10-Secoergosta-5,7,10(19),22-tetraen-3-ol
(5E,7E,22E)-9,10-Secoergosta-5,7,10,22-tetraen-3-ol
(5Z,7E,22E)-(3S)-9,10-seco-5,7,10(19),22-ergostatetraen-3-ol
(5Z,7E,22E)-(3S)-9,10-secoergosta-5,7,10(19),22-tetraen-3-ol
(5Z,7e,22e)-(3S)-9,10-Seco-5,7,10(19),22-ergostatetraen-3-ol
(5Z,7e,22e)-(3S)-9,10-Secoergosta-5,7,10(19),22-tetraen-3-ol
22-Tetraen 3beta 9,10,Secoergosta-5,7,10(19)-ol
31316-19-5
4-Methylene-3-[2-[tetrahydro-7a-methyl-1-(1,4,5-trimethyl-2-hexenyl)-4(3aH)-indanylidene]ethylidene]-Cyclohexanol
47768_SUPELCO
50-14-6
7489-18-1
7E677DC1-E1C4-4FC5-8F4A-BCE1857F7E87
8017-28-5
9,10,Secoergosta-5,7,10(19),22-tetraen 3.beta.-ol
9,10-Seco(5Z,7E,22E)-5,7,10(19),22-ergostatetraen-3-ol
9,10-Secoergosta-5,7,10(19),22-tetraen-3-beta-ol
9,10-Secoergosta-5,7,10(19),22-tetraen-3b-ol
95220_FLUKA
95220_SIGMA
AC-1355
AC1L1FIE
AC1NQXLH
AC1NS4DE
AC1NS9GI
AC1NSSVD
AC1NWAM3
AC1O5EDK
AC1O6WAM
ACon1_002187
Activated ergosterol
BPBio1_000418
BSPBio_000380
BSPBio_001974
Buco-D
C05441
C28H44O
CALCIFEROL IN A GELATIN MATRIX
CALCIFEROL, U.S.P.
CHEBI:28934
CHEMBL1536
CID11003810
CID3249
CID5280793
CID5315257
CID5353610
CID5356615
CID5702050
CID6432478
CID6536972
Calciferol
Calciferol (TN)
Calciferol (vitamin D2)
Calciferolum
Calciferon 2
Condacaps
Condocaps
Condol
Crtron
Crystallina
D-Arthin
D-Tracetten
D00187
DB00153
Daral
Davitamon D
Davitin
De-rat concentrate
Decaps
Dee-Osterol
Dee-Ron
Dee-Ronal
Dee-Roual
Deltalin
Deratol
Detalup
Diactol
Divit urto
Doral
Drisdol
Drisdol (TN)
E5750_SIGMA
EINECS 200-014-9
Ercalciol
Ergocalciferol
Ergocalciferol (D2)
Ergocalciferol (JP15/USP)
Ergocalciferol [INN:BAN:JAN]
Ergocalciferol oil
Ergocalciferol: Vitamin D
 
Ergocalciferolo
Ergocalciferolo [DCIT]
Ergocalciferols
Ergocalciferolum
Ergocalciferolum [INN-Latin]
Ergorone
Ergosterol activated
Ergosterol irradiated
Ergosterol, irradiated
Ertron
Fortodyl
Geltabs
Geltabs Vitamin D
HMS1920K20
HMS2091B19
HMS502I07
HSDB 819
Haliver
Hi-Deratol
Hyperkil
I05-0022
IDI1_000805
Infron
Irradiated ergosta-5,7,22-trien-3-beta-ol
Irradiated ergosta-5,7,22-trien-3.beta.-ol
Irradiated ergosta-5,7,22-trien-3beta-ol
Irradiated ergosterol
LMST03010001
LMST03010014
LS-3228
MEGxm0_000466
MLS001332467
MLS001332468
Metadee
Mina D2
MolPort-001-740-057
MolPort-001-793-930
MolPort-002-526-645
MolPort-003-666-178
MolPort-006-822-629
Mulsiferol
Mykostin
NCGC00142497-01
NCGC00179579-01
NCGC00179579-02
NSC 62792
NSC62792
Novovitamin-D
Oleovitamin D
Oleovitamin D, Synthetic
Oleovitamin D2
Osteil
Ostelin
Prestwick3_000420
Prestwick_554
Radiostol
Radstein
Radsterin
Rodine C
Rodinec
SMR000857106
SPECTRUM1500276
ST057150
STOCK1N-53397
Shock-ferol
Shock-ferol sterogyl
Sorex C.R
Sorex C.R.
Spectrum5_000666
Sterogyl
Synthetic Vitamin D
UNII-VS041H42XC
Uvesterol D
Uvesterol-D
VITAMIN D2
VITAMIN D2 WATER DISPERSABLE U.S.P.
VITAMIN_D2
Vigantol
Vio D
Vio-D
Viostdrol
Viosterol
Viosterol in Oil
Vitamin D2
Vitamin- D2
Vitamin-?D2
Vitamina D2
Vitavel-D
WLN: L56 FYTJ A1 BY1&1U1Y1&Y1&1 FU2U- BL6YYTJ AU1 DQ
ZINC04474571
ZINC04629876
beta-Ol
bmse000510
component of Geltabs Vitamin D
delta-Arthin
delta-Tracetten
ergocalciferol
vitamin d-2
8
Nicotinamideapproved, NutraceuticalPhase 4, Phase 2, Phase 191998-92-0936
Synonyms:
.beta.-Pyridinecarboxamide
11032-50-1
123574-63-0
1yc5
3 Pyridinecarboxamide
3-Carbamoylpyridine
3-Pyridinecarboxamide
3-Pyridinecarboxylic acid amide
37321-14-5
47865U_SUPELCO
55600-01-6
63748-44-7
72340_FLUKA
72340_SIGMA
72347_FLUKA
78731-47-2
98-92-0
A186B02E-6C70-4E54-9739-79398D439AAA
AC-907/25014114
AC1L1ACZ
AC1Q4ZFV
AI3-02906
Acid amide
Amid kyseliny nikotinove
Amid kyseliny nikotinove [Czech]
Amide PP
Aminicotin
Amixicotyn
Amnicotin
Astra Brand of Niacinamide
Austrovit PP
B 3, Vitamin
B3, Vitamin
BB_NC-2290
Benicot
C00153
C6H6N2O
CCRIS 1901
CHEBI:17154
CHEMBL1140
CID936
CPD000058212
D00036
D009536
DB02701
DEA No. 1405
Delonin Amide
Delonin amide
Dipegyl
Dipigyl
EINECS 202-713-4
EINECS 234-265-0
Endobion
Enduramide
Factor pp
HMS2052M21
HMS2090B05
HMS2093H03
HSDB 1237
Hansamid
I02-1741
I02-2250
InChI=1/C6H6N2O/c7-6(9)5-2-1-3-8-4-5/h1-4H,(H2,7,9
Inovitan PP
Jenapharm Brand of Niacinamide
Jenapharm, Nicotinsaureamid
LS-2051
MLS000069714
Mediatric
Merck Brand of Niacinamide
MolMap_000061
MolPort-001-783-876
N0078
N0636_SIGMA
N2142_SIGMA
N3376_SIGMA
N5535_SIAL
NAM
NCGC00093354-03
NCGC00093354-04
NSC 13128
NSC13128
NSC27452
Nandervit-N
Niacevit
Niacinamide
Niacinamide (USP)
Niacinamide Astra Brand
Niacinamide Jenapharm Brand
Niacinamide Merck Brand
 
Niacinamide Pharmagenix Brand
Niacinamide [USAN]
Niacinamide, Nicotinic acid amide, Nicotinamide
Niacotinamide
Niamide
Niavit PP
Nicamide
Nicamina
Nicamindon
Nicasir
Nicobion
Nicofort
Nicogen
Nicomidol
Nicosan 2
Nicosylamide
Nicota
Nicotamide
Nicotilamide
Nicotililamido
Nicotinamid
Nicotinamida
Nicotinamida [INN-Spanish]
Nicotinamide
Nicotinamide (JP15/INN)
Nicotinamide (Niacinamide)
Nicotinamide, niacin, vitamin B3
Nicotinamide-carbonyl-14C
Nicotinamidum
Nicotinamidum [INN-Latin]
Nicotine acid amide
Nicotine amide
Nicotinic acid amide
Nicotinic amide
Nicotinsaeureamid
Nicotinsaureamid
Nicotinsaureamid Jenapharm
Nicotinsaureamid [German]
Nicotol
Nicotylamide
Nicotylamidum
Nicovel
Nicovit
Nicovitina
Nicovitol
Nicozymin
Nictoamide
Nikasan
Nikazan
Niko-tamin
Nikotinamid
Nikotinsaeureamid
Nikotinsaeureamid [German]
Niocinamide
Niozymin
PP-Faktor
Papulex
Pelmin
Pelmine
Pelonin amide
Pharmagenix Brand of Niacinamide
Propamine A
Pyridine-3-carboxylic acid amide
S1899_Selleck
SAM001246860
SGCUT00176
SMR000058212
Savacotyl
UNII-25X51I8RD4
Vi-Nicotyl
Vi-noctyl
Vitamin B
Vitamin B (VAN)
Vitamin B 3
Vitamin B3 amide
Vitamin H1
Vitamin PP
WLN: T6NJ CVZ
Witamina PP
ZINC00005878
b-Pyridinecarboxamide
beta-Pyridinecarboxamide
bmse000281
m-(Aminocarbonyl)pyridine
nchembio.154-comp4
nchembio.73-comp6
niacin - Vitamin B3
niacinamide
nicotinamide
pyridine-3-carboxamide
to_000073
vitamin PP
9
Folic Acidapproved, nutraceutical, vet_approvedPhase 4, Phase 2, Phase 1439259-30-36037
Synonyms:
(2S)-2-[[4-[(2-amino-4-oxo-1H-pteridin-6-yl)methylamino]benzoyl]amino]pentanedioic acid
01769_FLUKA
2d0k
33609-88-0
36653-55-1 (mono-potassium salt)
59-30-3
6484-89-5 (mono-hydrochloride salt)
AC-11682
AC1L1LNX
AI3-26387
AKOS000503224
ARONIS014410
Acfol (Spain)
Acide folique
Acide folique [INN-French]
Acido folico
Acido folico [INN-Spanish]
Acidum folicum
Acidum folicum [INN-Latin]
Acifolic
Antianemia factor
Apo-Folic
BIDD:ER0563
BIDD:GT0641
BIF0608
BPBio1_000654
BSPBio_000594
BSPBio_002338
C00504
C20H20N6O6
CAS-59-30-3
CCRIS 666
CHEBI:27470
CHEMBL1622
CID6037
CPD000471860
Cytofol
D00070
DB00158
DivK1c_000494
Dosfolat B activ
EINECS 200-419-0
F0043
F7876_SIAL
F7876_SIGMA
F8758_SIGMA
F8798_SIAL
F8890_SIGMA
FOL
Facid
Factor U
Folacid
Folacin
Folaemin
Folaemin [Netherlands]
Folan
Folasic (Australia)
Folate
Folbal
Folcidin
Folcidin (VAN)
Folcysteine
Foldine
Foldine [France]
Folettes
Foliamin
Folic
Folic acid
Folic acid (JP15/USP/INN)
Folic acid (TN)
Folic acid [BAN:INN:JAN]
Folic acid [INN:BAN:JAN]
Folic acid dihydrate
Folicet
Folicet (TN)
Folico
Folico (Italy)
Folina
Folina (Italy)
Folipac
Folsaeure
 
Folsan
Folsaure
Folsav
Folvite
Folvron
Glutamic acid, N-(p-(((2-amino-4-hydroxypyrimido(4,5-b)pyrazin-6-yl)methyl)amino)benzoyl)-, L
HMS1921D20
HMS2092N17
HMS501I16
HSDB 2002
IDI1_000494
InChI=1/C19H19N7O6/c20-19-25-15-14(17(30)26-19)23-11(8-22-15)7-21-10-3-1-9(2-4-10)16(29)24-12(18(31)32)5-6-13(27)28/h1-4,8,12,21H,5-7H2,(H,24,29)(H,27,28)(H,31,32)(H3,20,22,25,26,30)/t12-/m0/s
Incafolic
KBio1_000494
KBio2_001861
KBio2_004429
KBio2_006997
KBio3_001558
KBioGR_002222
KBioSS_001861
Kyselina listova
Kyselina listova [Czech]
LS-2157
Liver Lactobacillus casei factor
MLS001304016
MLS001335861
Millafol
Mission prenatal
Mittafol
MolPort-004-285-551
N-(4-(((2-Amino-1,4-dihydro-4-oxo-6-pteridinyl)methyl)amino)benzo- yl)-L-glutamic acid
N-(4-((2-Amino-1,4-dihydro-4-oxo-6-pteridinyl)methyl)amino)benzoyl)-L-glutamic acid
N-(4-{[(2-Amino-4-oxo-3,4-dihydropteridin-6-yl)methyl]amino}benzoyl)-L-glutamic acid
N-(4-{[(2-amino-4-oxo-1,4-dihydropteridin-6-yl)methyl]amino}benzoyl)-L-glutamic acid
N-(p-(((2-Amino-4-hydroxy-6-pteridinyl)methyl)amino)benzoyl)-L-glutamic acid
N-Pteroyl-L-glutamic acid
N-[(4-{[(2-Amino-4-oxo-1,4-dihydropteridin-6-yl)methyl]amino}phenyl)carbonyl]-L-glutamic acid
N-[(4-{[(2-amino-4-oxo-1,4-dihydropteridin-6-yl)methyl]amino}phenyl)carbonyl]-L-glutamic acid
N-[4-[[(2-Amino-3,4-dihydro-4-oxo-6-pteridinyl)methyl]amino]benzoyl]-L-glutamic acid
NCGC00016265-01
NCGC00142391-01
NINDS_000494
NSC 3073
Nifolin
Nifolin [Denmark]
Novofolacid
Novofolacid [Canada]
PGA
PGA (VAN)
Prestwick3_000627
Prestwick_230
PteGlu
Pteroyl-L-glutamate
Pteroyl-L-glutamic acid
Pteroyl-L-monoglutamate
Pteroyl-L-monoglutamic acid
Pteroylglutamate
Pteroylglutamic acid
Pteroylmonoglutamate
Pteroylmonoglutamic acid
SAM002264616
SDCCGMLS-0066738.P001
SMP2_000137
SMR000471860
SPBio_001357
SPECTRUM1502020
Serum Folate Level
Spectrum2_001459
Spectrum3_000749
Spectrum4_001751
Spectrum5_000602
Spectrum_001381
UNII-935E97BOY8
Usaf cb-13
Vitamin B11
Vitamin B9
Vitamin Bc
Vitamin Be
Vitamin M
bmse000299
folic acid
nchembio.108-comp10
10
Niacinapproved, investigational, nutraceuticalPhase 4, Phase 2, Phase 192359-67-6938
Synonyms:
3-Carboxylpyridine
3-Carboxypyridine
3-Pyridinecarboxylate
3-Pyridinecarboxylic acid
3-Pyridylcarboxylate
3-Pyridylcarboxylic acid
3-carboxypyridine
Acide Nicotinique
Acido nicotinico
Acidum Nicotinicum
Akotin
Anti-pellagra vitamin
Apelagrin
Daskil
Efacin
Enduracin
Linic
M-Pyridinecarboxylic Acid
Niac
Niacin
Niacine
Niacor
Nicacid
Nicamin
Nicangin
 
Nico-Span
Nicobid
Nicocap
Nicodelmine
Nicolar
Niconacid
Nicosan 3
Nicotinate
Nicotinic Acid
Nicotinic acid
Nicotinipca
Nicyl
Nikotinsaeure
Nyclin
P.P. factor
PP Factor
Pellagra preventive factor
Pellagrin
Pelonin
Pyridine-beta-carboxylic acid
Slo-niacin
Vitamin B3
Wampocap
beta-Pyridinecarboxylic acid
pyridine-β-carboxylic acid
β-pyridinecarboxylic acid
11
Alfacalcidolapproved, nutraceuticalPhase 46141294-56-85282181
Synonyms:
(5Z,7e)-9,10-Seco-5,7,10(19)-cholestatrien-1alpha,3beta-diol
1-Hydroxycholecalciferol
1-hydroxycholecalciferol
1alpha-Hydroxy-vitamin D3
 
1alpha-hydroxycholecalciferol
1alpha-hydroxyvitamin D3
9,10-Secocholesta-5,7,10(19)-triene-1alpha,3beta-diol
Alfacalcidolum
Alsiodol
12
Calcitriolapproved, nutraceuticalPhase 4, Phase 221032222-06-3134070, 5280453
Synonyms:
(1R,3S)-5-{2-[(1R,3aS,7aR)-1-((R)-5-Hydroxy-1,5-dimethyl-hexyl)-7a-methyl-octahydro-inden-4-ylidene]-ethylidene}-4-methylene-cyclohexane-1,3-diol
(1R,3S,5Z)-5-[(2E)-2-[(1R,3aS,7aR)-1-[(2R)-6-hydroxy-6-methylheptan-2-yl]-7a-methyl-2,3,3a,5,6,7-hexahydro-1H-inden-4-ylidene]ethylidene]-4-methylidenecyclohexane-1,3-diol
(1S,3R,5Z,7E)-9,10-secocholesta-5,7,10(19)-triene-1,3,25-triol
(1S,3R,5Z,7E)-9,10-secocholesta-5,7,10-triene-1,3,25-triol
(1alpha,3beta,5Z,7E)-9,10-secocholesta-5,7,10(19)-triene-1,3,25-triol
(1α,3β,5Z,7E)-9,10-secocholesta-5,7,10(19)-triene-1,3,25-triol
(3b,5Z,7E)-9,10-Secocholesta-5,7,10(19)-trienetriol
(5Z,7E)-(1S,3R)-9,10-secocholesta-5,7,10(19)-triene-1,3,25-triol
(5Z,7E)-9,10-Secocholesta-5,7,10(19)-triene-1-alpha,3-beta,25-triol
(5Z,7E)-9,10-Secocholesta-5,7,10(19)-triene-1alpha,3beta,25-triol
1 alpha,25-Dihydroxyvitamin D3
1,25 (OH)2 D3
1,25 Dihydroxycholecalciferol
1,25(OH)2-20epi-D3
1,25(OH)2D3 & CD4
1,25(OH2)D3
1,25-(OH)2-D3
1,25-(OH)2D3
1,25-DHCC
1,25-DIHYDROXYCHOLECALCIFEROL
1,25-Dihydroxycholecalciferol
1,25-Dihydroxycholecaliferol
1,25-Dihydroxyvitamin D
1,25-Dihydroxyvitamin D3
1,25-dihydroxy vitamin D3
1,25-dihydroxy-20-epi-Vitamin D3
1,25-dihydroxycholecalciferol
1,25D3
1-alpha,-1,25-Dihydroxyvitamin D3
1-alpha,25-Dihydroxycholecalciferol
1-alpha,25-Dihydroxyvitamin D3
1-alpha-25-Dihydroxyvitamin D3
1-alpha-25-dihydroxyvitamin D3
1.Alpha.,25-Dihydroxy-26,27-hexadeuterovitamin D3
17936_FLUKA
17936_SIGMA
1a,25-(OH)2D3
1a,25-Dihydroxycholecalciferol
1a,25-Dihydroxyvitamin D3
1alpha,25(OH)2-D3
1alpha,25(OH)2D3
1alpha,25-Dihydroxycholecalciferol
1alpha,25-Dihydroxyvitamin D
1alpha,25-Dihydroxyvitamin D3
1db1
1α,25(OH)2D3
1α,25-dihydroxycholecalciferol
1α,25-dihydroxyvitamin D3
20-epi-1alpha,25-dihydroxycholecaliferol
25-Dihydroxycholecalciferol
32222-06-3
9,10-Seco(5Z,7E)-5,7,10(19)-cholestatriene-1alpha,3beta,25-triol
9,10-Secocholesta-5,7,10(19)-triene-1,3,25-triol, (1.alpha.,3.beta,.5Z,7E)- & CD4
9,10-seco(5Z,7E)-5,7,10(19)-cholestatriene-1alpha, 3beta, 25-triol
AC-1859
AC1NQX1S
Ambap32222-06-3
 
Asentar
BCBcMAP01_000160
BML2-E03
BSPBio_001287
C01673
CCRIS 5522
CD-2027
CHEBI:17823
CHEMBL846
CID5280453
CPD000466393
Calcijex
Calcijex, Silkis, Rocaltrol, Topitriol, Cholecalciferol,Calcitriol
Calcitriol
Calcitriol (JAN/USAN/INN)
Calcitriol [USAN:INN:BAN:JAN]
Calcitriolum
Calcitriolum [INN-Latin]
D00129
D1530_SIGMA
DN 101
DN-101
Decostriol
Dihydroxyvitamin D3
EINECS 250-963-8
HMS1361A09
HMS1791A09
HMS1989A09
HMS2051F06
HMS2089N03
HSDB 3482
IDI1_033757
LMST03020258
LS-53093
MC-1288
MC1288
MLS000759536
MLS001424122
MolPort-002-045-698
NCGC00161327-01
NCGC00161327-04
Ro 21-5535
Ro 215535
Ro-21-5535
Rocaltrol
Rocaltrol (TN)
S1466_Selleck
SAM001246772
SMR000466393
Silkis
Soltriol
Spectrum5_002061
Topitriol
Toptriol
U 49562
Vectical
ZINC03924790
calcitriol
vit D
13
Vitamin Capproved, nutraceuticalPhase 453150-81-75785, 54670067
Synonyms:
(+)-Sodium L-ascorbate
(+)-ascorbate
(+)-ascorbic acid
(2R)-2-[(1S)-1,2-Dihydroxyethyl]-4,5-dihydroxy-furan-3-one
(2R)-2-[(1S)-1,2-dihydroxyethyl]-4,5-dihydroxyfuran-3-one
(5R)-5-[(1S)-1,2-dihydroxyethyl]-3,4-dihydroxyfuran-2(5H)-one
129940-97-2
134-03-2 (monosodium salt)
14536-17-5
154170-90-8
2-(1,2-Dihydroxyethyl)-4,5-dihydroxyfuran-3-one
255564_SIAL
259133-78-3
3-Keto-L-gulofuranolactone
3-Oxo-L-gulofuranolactone
3-Oxo-L-gulofuranolactone (enol form)
30208-61-8
33034_RIEDEL
33034_SIAL
47863_SUPELCO
47A605F0-4187-47A8-B0CE-F9E7DA1B0076
50-81-7
50976-75-5
56172-55-5
56533-05-2
57304-74-2
57606-40-3
623158-95-2
6730-29-6
882690-91-7
884381-69-5
885512-24-3
88845-26-5
89924-69-6
95209_FLUKA
95209_SIGMA
95210_FLUKA
95210_SIAL
95212_FLUKA
A0278_SIGMA
A0537
A2174_SIGMA
A2218_SIGMA
A2343_SIGMA
A4403_SIGMA
A4544_SIGMA
A5960_SIGMA
A7506_SIGMA
A92902_ALDRICH
A92902_SIAL
AB00376923
AB1002440
AC1L1L4T
AC1Q77S6
AR-1J3435
Acid Ascorbic
Acide ascorbique
Acide ascorbique [INN-French]
Acido ascorbico
Acido ascorbico [INN-Spanish]
Acidum ascorbicum
Acidum ascorbicum [INN-Latin]
Acidum ascorbinicum
Adenex
Allercorb
Ambap36431-82-0
Antiscorbic vitamin
Antiscorbutic factor
Antiscorbutic vitamin
Arco-cee
Ascoltin
Ascoltin (TN)
Ascor-B.I.D.
Ascorb
Ascorbajen
Ascorbate
Ascorbic Acid
Ascorbic Acid, Monosodium Salt
Ascorbic acid
Ascorbic acid (JP15/USP/INN)
Ascorbic acid [BAN:INN:JAN]
Ascorbic acid [INN:BAN:JAN]
Ascorbicab
Ascorbicap
Ascorbicap (TN)
Ascorbicin
Ascorbin
Ascorbinsaeure
Ascorbinsäure
Ascorbutina
Ascorbyl radical
Ascorin
Ascorteal
Ascorvit
BPBio1_000363
BSPBio_000329
C-Level
C-Long
C-Quin
C-Span
C-Vimin
C00072
C6H8O6
CCRIS 57
CE-VI-Sol
CHEBI:29073
CHEMBL196
CID5785
Cantan
Cantaxin
Caswell No. 061B
Catavin C
Ce lent
Ce-Mi-Lin
Ce-mi-lin
Ce-vi-sol
Cebicure
Cebid
Cebion
Cebione
Cecon
Cee-Caps TD
Cee-Vite
Cee-caps TD
Cee-vite
Cegiolan
Ceglion
Ceklin
Celaskon
Celin
Cell C
Cemagyl
Cemill
Cenetone
Cenolate
Cereon
Cergona
Cescorbat
Cetamid
Cetane
Cetane-Caps TC
Cetane-Caps TD
Cetane-caps TC
Cetane-caps TD
Cetebe
Cetemican
Cevalin
 
Cevatine
Cevex
Cevi-Bid
Cevi-bid
Cevimin
Cevital
Cevitamate
Cevitamic acid
Cevitamin
Cevitan
Cevitex
Cewin
Chewcee
Ciamin
Cipca
Citriscorb
Citrovit
Colascor
Concemin
Cortalex
D00018
DB00126
Davitamon C
Dora-C-500
Duoscorb
EINECS 200-066-2
FEMA No. 2109
Ferancee
Ferrous ascorbate
HSDB 818
HiCee
Hicee
Hybrin
IDO-C
Ido-C
Iron(II) ascorbate
Iron-ascorbic acid complexes
Juvamine
Kangbingfeng
Kyselina askorbova
Kyselina askorbova [Czech]
L(+)-Ascorbate
L(+)-Ascorbic acid
L-(+)-Ascorbate
L-(+)-Ascorbic Acid
L-(+)-Ascorbic acid
L-(+)-ascorbic acid
L-3-Ketothreohexuronic acid lactone
L-3-ketothreohexuronic acid
L-Ascorbate
L-Ascorbic Acid
L-Ascorbic acid
L-Ascorbic acid, free radical form
L-Lyxoascorbate
L-Lyxoascorbic acid
L-Threo-ascorbic acid
L-Threoascorbic acid
L-Xyloascorbate
L-Xyloascorbic acid
L-ascorbate
L-threo-Hex-2-enonic acid, gamma-lactone
L-threo-ascorbic acid
L-threo-hex-2-enono-1,4-lactone
LS-145
Laroscorbine
Lemascorb
Liqui-Cee
Liqui-cee
MLS002153776
Magnesium Ascorbicum
Magnorbin
Meri-C
Meri-c
MolPort-001-792-501
Monodehydroascorbic acid
NCGC00091517-01
NCGC00091517-02
NCGC00164357-01
NCI-C54808
NSC 33832
Natrascorb
Natrascorb injectable
Oral Vitamin C
Planavit C
Prestwick3_000325
Proscorbin
Redoxon
Ribena
Ronotec 100
Rontex 100
Roscorbic
Rovimix C
SMR001233160
Scorbacid
Scorbu C
Scorbu-C
Secorbate
Semidehydroascorbate
Sodascorbate
Sodium Ascorbate (Ascorbic Acid)
Stuartinic
Suncoat VC 40
Sunkist
Testascorbic
Tolfrinic
UNII-PQ6CK8PD0R
VASC
Vicelat
Vicin
Vicomin C
Viforcit
Viscorin
Viscorin 100M
Vitace
Vitacee
Vitacimin
Vitacin
Vitamin C
Vitamin- C
Vitamin-?C
Vitamisin
Vitascorbol
W210901_ALDRICH
Xitix
acide ascorbique
acidum ascorbicum
acidum ascorbinicum
antiscorbic vita min
ascor-b.i.d
ascorbate
ascorbic acid
bmse000182
cee-caps td
cevibid
component of Cortalex
component of E and C-Level
component of Endoglobin Forte
component of Ferancee
gamma-Lactone L-threo-Hex-2-enonate
gamma-Lactone L-threo-Hex-2-enonic acid
l-ascorbic acid
l-threo-hex-1-eofuranos-3-ulose
nchembio.174-comp5
nchembio.89-comp1
nchembio.92-comp2
nchembio821-comp9
roscorbi c
vitamin C
ácido ascórbico
14VitaminsPhase 4, Phase 3, Phase 2, Phase 15282
15vitamin dPhase 4, Phase 3, Phase 21724
16Trace ElementsPhase 4, Phase 3, Phase 2, Phase 16001
17Chelating AgentsPhase 4, Phase 3, Phase 2, Phase 11423
18Bone Density Conservation AgentsPhase 4, Phase 3, Phase 2, Phase 13376
19Calcium, DietaryPhase 4, Phase 3, Phase 2, Phase 15713
20ErgocalciferolsPhase 4, Phase 21281
21HormonesPhase 4, Phase 314415
22MicronutrientsPhase 4, Phase 3, Phase 2, Phase 16001
23Ferric CompoundsPhase 4, Phase 3, Phase 2194
24HematinicsPhase 4, Phase 3, Phase 21684
25Hormone AntagonistsPhase 413180
26Hormones, Hormone Substitutes, and Hormone AntagonistsPhase 413168
27Vitamin B ComplexPhase 4, Phase 2, Phase 14337
28AnticoagulantsPhase 4, Phase 3, Phase 2, Phase 12623
29Protective AgentsPhase 4, Phase 27443
30Cinacalcet HydrochloridePhase 471
31Vasodilator AgentsPhase 4, Phase 2, Phase 13543
32Nicotinic AcidsPhase 4, Phase 2, Phase 1923
33Anticholesteremic AgentsPhase 42025
34Vasoconstrictor AgentsPhase 4, Phase 22122
35Pharmaceutical SolutionsPhase 4, Phase 3, Phase 18192
36HydroxycholecalciferolsPhase 4129
37AntacidsPhase 4, Phase 3, Phase 21842
38Anti-Ulcer AgentsPhase 4, Phase 3, Phase 21842
39Calcimimetic AgentsPhase 471
40AntimetabolitesPhase 4, Phase 2, Phase 112054
41Lipid Regulating AgentsPhase 4, Phase 2, Phase 12766
42Liver ExtractsPhase 44067
43Hypolipidemic AgentsPhase 4, Phase 2, Phase 12785
44Hydroxymethylglutaryl-CoA Reductase InhibitorsPhase 41998
45Atorvastatin CalciumPhase 4760134523-03-8
46Gastrointestinal AgentsPhase 4, Phase 3, Phase 2, Phase 18402
47AntioxidantsPhase 43050
48Vitamin D2NutraceuticalPhase 4, Phase 21281
49CalciferolNutraceuticalPhase 4, Phase 21383
50Vitamin B3NutraceuticalPhase 4, Phase 2, Phase 1923

Interventional clinical trials:

(show top 50)    (show all 159)
idNameStatusNCT IDPhase
1Alendronate for Vascular Calcification in Peritoneal Dialysis Patients?Unknown statusNCT00299572Phase 4
2More Frequent Dialysis (>3 Treatments Per Week)Unknown statusNCT00575497Phase 4
3Fosrenol Post-marketing Surveillance for Continuous Cyclic Peritoneal Dialysis in JapanCompletedNCT01412398Phase 4
4Long Term Evaluation of Sevelamer HCl vs. Calcium-based Phosphate Binder in the Treatment of Hyperphosphatemia in Hemodialysis PatientsCompletedNCT01755078Phase 4
5Phosphate Kinetic Modeling 2CompletedNCT01252771Phase 4
6Efficacy and Safety of Fosrenol in Treating Elevated Serum Phosphate Levels in Adults With End Stage Renal DiseaseCompletedNCT00160121Phase 4
7Initial Dosing of Paricalcitol in Secondary HyperparathyroidismCompletedNCT00307840Phase 4
8Efficacy and Safety of Alfacalcidol Compared to Calcitriol for Treatment of Secondary HyperparathyroidismCompletedNCT01115543Phase 4
9Effectiveness and Safety of IV Zemplar in Patients on Hemodialysis and With Secondary Hyperparathyroidism Using iPTH/100 as Initial DoseCompletedNCT00891813Phase 4
10Study to Compare Initial Dosing Parameters of Zemplar in Stage V Chronic Kidney Disease Subjects on HemodialysisCompletedNCT00091481Phase 4
11Equivalence of Calcium Acetate Oral Solution and Sevelamer Carbonate Tablets in Hemodialysis PatientsCompletedNCT01427907Phase 4
12CARE-2 (Calcium Acetate [PhosLo®]/Sevelamer[Renagel®] Evaluation Study 2) for Heart Calcification in Dialysis PatientsCompletedNCT00211939Phase 4
13Efficacy and Safety of 6 Months Treatment With Paricalcitol Injection or Oral in Patients With Secondary Hyperparathyroidism on DialysisCompletedNCT00537979Phase 4
1420070360 Incident DialysisCompletedNCT00803712Phase 4
15Nicotinic Acid in Hemodialysis Patients With HyperphosphatemiaRecruitingNCT02836184Phase 4
16A Study of Ferric Citrate to Improve Inflammation and Lipid LevelsRecruitingNCT02661295Phase 4
17Phosphate Lowering to Treat Vascular Dysfunction in Chronic Kidney DiseaseRecruitingNCT02209636Phase 4
18Lanthanum Versus Calcium Carbonate for Vascular Abnormalities in Patients With CKD and HyperphosphatemiaEnrolling by invitationNCT02237534Phase 4
19The Efficacy of Niacin on Hyperphosphatemia in Patients Undergoing HaemodialysisNot yet recruitingNCT03163576Phase 4
20Transition to Ferric Citrate Among Hemodialysis and Peritoneal Dialysis PatientsNot yet recruitingNCT03079869Phase 4
21Conversion From Standard Phosphate Binder Therapy to Fosrenol® (Lanthanum Carbonate) in Chronic Kidney Disease Stage 5TerminatedNCT00452478Phase 4
22Management of Mineral and Bone Disease in Hemodialysis-Calcitriol vs. ParicalcitolTerminatedNCT01725113Phase 4
23Vitamin D and Carboxy PTH Fragments in Coronary CalcificationWithdrawnNCT00502268Phase 4
24Study Comparing Effects of Lanthanum Carbonate Versus Calcium Acetate Versus Dietary Phosphorus RestrictionUnknown statusNCT01357317Phase 3
25A Long-term Study of PA21 in Hemodialysis Patients With HyperphosphatemiaCompletedNCT01833494Phase 3
26An 8-Week Study to Evaluate Tenapanor in the Treatment of Hyperphosphatemia in End-Stage Renal Disease Patients on Hemodialysis (ESRD-HD)CompletedNCT02675998Phase 3
27Open Study of BAY77-1931 (Lanthanum Carbonate) in Continuous Ambulatory Peritoneal Dialysis PatientsCompletedNCT01518387Phase 3
28Phase III Double-blind Comparative Study of BAY77-1931 (Lanthanum Carbonate) With Calcium CarbonateCompletedNCT01514851Phase 3
29Study of MCI-196 in Chronic Kidney Disease Stage V Subjects on Dialysis With HyperphosphatemiaCompletedNCT00772382Phase 3
30A Phase III Study of PA21 in Hemodialysis Patients With HyperphosphatemiaCompletedNCT01850602Phase 3
31Long-term Study in Patients With Chronic Kidney Disease and Hyperphosphatemia on HemodialysisCompletedNCT00892749Phase 3
32A Phase III Study of PA21 in Peritoneal Dialysis Patients With HyperphosphatemiaCompletedNCT01852682Phase 3
33A Phase III Study of PA21 With Calcium Carbonate in Hemodialysis Patients With HyperphosphatemiaCompletedNCT01850641Phase 3
34Long-term Study in Chronic Kidney Disease Patients With Hyperphosphatemia Not on DialysisCompletedNCT01742611Phase 3
35A Phase 3 Study of ASP1585 in Chronic Kidney Disease Patients With Hyperphosphatemia Not on DialysisCompletedNCT01742585Phase 3
36A Phase III, Multicentre, Double-Blind, Placebo-Controlled Withdrawal Study in Patients With HyperphosphatemiaCompletedNCT00416520Phase 3
37A Study of MCI-196 in Chronic Kidney Disease Stage V Subjects on Dialysis With HyperphosphatemiaCompletedNCT00542815Phase 3
38A Phase 3 Study in Patients With Chronic Kidney Disease and Hyperphosphatemia on Peritoneal DialysisCompletedNCT01017276Phase 3
39A Comparative Study of ASP1585 in Chronic Kidney Disease Patients With Hyperphosphatemia on HemodialysisCompletedNCT01057407Phase 3
40A Phase 3, Randomized, Double Blind, Placebo-Controlled, Multi-Center, Withdrawal Study of MCI-196 in CKD on Dialysis With HyperphosphatemiaCompletedNCT00506441Phase 3
41Long-term Study in Chronic Kidney Disease (Extension From Study 14817)CompletedNCT01187628Phase 3
42A Study of MCI-196 in Chronic Kidney Disease Subjects on Dialysis With Hyperphosphatemia and DyslipidaemiaCompletedNCT00542386Phase 3
43Study in Chronic Kidney Disease (CKD) Not on DialysisCompletedNCT01110629Phase 3
44A Phase 3 Study to Investigate the Safety and Efficacy of PA21, a Phosphate Binder, in Dialysis PatientsCompletedNCT01324128Phase 3
45Placebo Versus SBR759 in Lowering Phosphate in Dialysis PatientsCompletedNCT01069692Phase 3
46A Phase 3 Extension Study to Investigate the Long-term Safety, Tolerability and Efficacy of PA21, a Phosphate Binder in Dialysis PatientsCompletedNCT01464190Phase 3
47A 4-Week Dose-Ranging and Efficacy Trial of KRX-0502 (Ferric Citrate) in Patients With End-Stage Renal DiseaseCompletedNCT01074125Phase 3
48Therapeutic Equivalence of OsvaRen® Tablets and OsvaRen® GranulesCompletedNCT02027662Phase 2, Phase 3
49A 58-Week Safety and Efficacy Trial of Ferric Citrate in Patients With ESRD on DialysisCompletedNCT01191255Phase 3
50An Open Label Dose Titration of Sevelamer Carbonate Tabs 3 Times a Day in Hyperphosphatemic CKD Patients Not On DialysisCompletedNCT00681941Phase 3

Search NIH Clinical Center for Hyperphosphatemia


Cochrane evidence based reviews: hyperphosphatemia

Genetic Tests for Hyperphosphatemia

About this section

Genetic tests related to Hyperphosphatemia:

id Genetic test Affiliating Genes
1 Hyperphosphatemia27

Anatomical Context for Hyperphosphatemia

About this section

MalaCards organs/tissues related to Hyperphosphatemia:

36
Kidney, Bone, Smooth muscle, Colon, Endothelial, Liver, Retina

Publications for Hyperphosphatemia

About this section

Articles related to Hyperphosphatemia:

(show top 50)    (show all 436)
idTitleAuthorsYear
1
Transient hyperphosphatemia in a child with nephrolithiasis and severe prematurity. (28325562)
2017
2
Development of a novel chronic kidney disease mouse model to evaluate the progression of hyperphosphatemia and associated mineral bone disease. (28533541)
2017
3
Hyperphosphatemia and hs-CRP Initiate the Coronary Artery Calcification in Peritoneal Dialysis Patients. (28321403)
2017
4
Net Budgetary Impact of Ferric Citrate as a First-Line Phosphate Binder for the Treatment of Hyperphosphatemia: A Markov Microsimulation Model. (28078600)
2017
5
Spurious Hyperphosphatemia: A Diagnostic and Therapeutic Challenge. (26706383)
2016
6
Economic Evaluation of Sevelamer versus Calcium-based Binders in Treating Hyperphosphatemia among Patients with End-stage Renal Disease in China. (27751671)
2016
7
Treating hyperphosphatemia - current and advancing drugs. (27643443)
2016
8
Erratum to: Dose-response efficacy and safety of PA21 in Japanese hemodialysis patients with hyperphosphatemia: a randomized, placebo-controlled, double-blind, Phase II study. (27832343)
2016
9
Effect of low dose nicotinic acid on hyperphosphatemia in patients with end stage renal disease. (27512294)
2016
10
Efficacy and safety of osteoporosis medications in a rat model of late-stage chronic kidney disease accompanied by secondary hyperparathyroidism and hyperphosphatemia. (27933339)
2016
11
Ornithine is a key mediator in hyperphosphatemia-mediated human umbilical vein endothelial cell apoptosis: Insights gained from metabolomics. (26773858)
2016
12
Short-Term PTH(1-34) Therapy in Children to Correct Severe Hypocalcemia and Hyperphosphatemia due to Hypoparathyroidism: Two Case Studies. (27957353)
2016
13
Sevelamer is an Effective Drug in Treating Hyperphosphatemia Due to Tumor Lysis Syndrome in Children: A Developing World Experience. (26855510)
2016
14
Phenotypic and Genotypic Characterization and Treatment of a Cohort with Familial Tumoral Calcinosis/Hyperostosis-Hyperphosphatemia Syndrome. (27164190)
2016
15
Incremental cost-utility of sevelamer relative to calcium carbonate for treatment of hyperphosphatemia among pre-dialysis chronic kidney disease patients. (27121505)
2016
16
Efficacy and safety of calcium acetate-magnesium carbonate in the treatment of hyperphosphatemia in dialysis patients. (27900961)
2016
17
Severe hyperphosphatemia after oral laxative administration in a 7-year-old patient. (27922249)
2016
18
Dose-response efficacy and safety of PA21 in Japanese hemodialysis patients with hyperphosphatemia: a randomized, placebo-controlled, double-blind, Phase II study. (27389681)
2016
19
Sevelamer Versus Calcium-Based Binders for Treatment of Hyperphosphatemia in CKD: A Meta-Analysis of Randomized Controlled Trials. (26668024)
2016
20
Hyperphosphatemia Management in Patients with Chronic Kidney Disease. (27330380)
2016
21
The efficacy and safety of sevelamer and lanthanum versus calcium-containing and iron-based binders in treating hyperphosphatemia in patients with chronic kidney disease: a systematic review and meta-analysis. (27651467)
2016
22
Chronic Hyperphosphatemia and Vascular Calcification Are Reduced by Stable Delivery of Soluble Klotho. (27837149)
2016
23
Transient hyperphosphatemia: a benign laboratory disorder in a boy with Gitelman syndrome. (27737396)
2016
24
Hyperphosphatemia. The hidden killer in chronic kidney disease. (25629999)
2015
25
Ferric citrate (auryxia) for the treatment of hyperphosphatemia. (25987821)
2015
26
Human Preosteoblastic Cell Culture from a Patient with Severe Tumoral Calcinosis-Hyperphosphatemia Due to a New GALNT3 Gene Mutation: Study of In Vitro Mineralization. (25899975)
2015
27
Hyperphosphatemia induces cellular senescence in human aorta smooth muscle cells through integrin linked kinase (ILK) up-regulation. (26467393)
2015
28
Additional benefit of dietitian involvement in dialysis staffs-led diet education on uncontrolled hyperphosphatemia in hemodialysis patients. (26658792)
2015
29
Calcium acetate or calcium carbonate for hyperphosphatemia of hemodialysis patients: a meta-analysis. (25799184)
2015
30
Hyperphosphatemia in Dialysis Patients: Beyond Nonadherence to Diet and Binders. (26508681)
2015
31
Hyperphosphatemia as an independent risk factor for coronary artery calcification progression in peritoneal dialysis patients. (26187601)
2015
32
Novel iron-containing phosphate binders for treatment of hyperphosphatemia. (26293683)
2015
33
Hyperphosphatemia induces protective autophagy in endothelial cells through the inhibition of Akt/mTOR signaling. (24797554)
2015
34
Ferric citrate (Auryxia) for hyperphosphatemia. (26633686)
2015
35
Effect of individual health education on hyperphosphatemia in the Hakkas residential area. (26275110)
2015
36
Iron, Aluminum, and Lanthanum-based Drugs for Treatment of Hyperphosphatemia. (25832833)
2015
37
Safety and efficacy evaluation of lanthanum carbonate for hyperphosphatemia in end-stage renal disease patients. (26023014)
2015
38
Randomized, Double-Blind, Placebo-Controlled, Withdrawal Study of Colestilan after Dose Titration in Chronic Kidney Disease Dialysis Patients with Hyperphosphatemia. (26184491)
2015
39
Survival advantage of lanthanum carbonate for hemodialysis patients with uncontrolled hyperphosphatemia. (25422311)
2015
40
Efficacy and safety of nicotinamide in the management of hyperphosphatemia in pediatric patients on regular hemodialysis. (26420678)
2015
41
Fetuin-A decrease induced by a low-protein diet enhances vascular calcification in uremic rats with hyperphosphatemia. (26180236)
2015
42
Hyperphosphatemia Is an Independent Risk Factor for Mortality in Critically Ill Patients: Results from a Cross-Sectional Study. (26252874)
2015
43
Sevelamer Hydrochloride for Tumor Lysis Syndrome-related Hyperphosphatemia. (26244958)
2015
44
Bixalomer, a novel phosphate binder with a small swelling index, improves hyperphosphatemia in chronic kidney disease rat. (26452517)
2015
45
Improving diet recipe and cooking methods attenuates hyperphosphatemia in patients undergoing peritoneal dialysis. (26141941)
2015
46
Advances in pharmacotherapy for hyperphosphatemia in renal disease. (26374200)
2015
47
Hyperphosphatemia is associated with patency loss of arteriovenous fistula after 1 year of hemodialysis. (26484018)
2015
48
Wakame (Undaria pinnatifida ) modulates hyperphosphatemia in a rat model of chronic renal failure. (25817287)
2015
49
Hyperphosphatemia, Phosphoprotein Phosphatases, and Microparticle Release in Vascular Endothelial Cells. (25745026)
2015
50
Managing hyperphosphatemia in patients with chronic kidney disease on dialysis with ferric citrate: latest evidence and clinical usefulness. (26336594)
2015

Variations for Hyperphosphatemia

About this section

Expression for genes affiliated with Hyperphosphatemia

About this section
Search GEO for disease gene expression data for Hyperphosphatemia.

Pathways for genes affiliated with Hyperphosphatemia

About this section

GO Terms for genes affiliated with Hyperphosphatemia

About this section

Cellular components related to Hyperphosphatemia according to GeneCards Suite gene sharing:

idNameGO IDScoreTop Affiliating Genes
1apical plasma membraneGO:00163248.8CASR, GNAS, KL, SLC34A1

Biological processes related to Hyperphosphatemia according to GeneCards Suite gene sharing:

(show all 20)
idNameGO IDScoreTop Affiliating Genes
1cellular response to vitamin DGO:007130510.6CASR, FGF23
2cellular response to parathyroid hormone stimulusGO:007137410.5FGF23, SLC34A1
3phosphate ion homeostasisGO:005506210.5FGF23, SLC34A1
4positive regulation of vitamin D 24-hydroxylase activityGO:001098010.5FGF23, VDR
5response to magnesium ionGO:003202610.5FGF23, SLC34A1
6response to fibroblast growth factorGO:007177410.3CASR, PTH
7response to cadmium ionGO:004668610.3PTH, SLC34A1
8response to lead ionGO:001028810.3PTH, SLC34A1
9embryonic cranial skeleton morphogenesisGO:004870110.3GNAS, RUNX2
10endochondral ossificationGO:000195810.3GNAS, RUNX2
11regulation of bone mineralizationGO:003050010.3FGF23, MGP
12positive regulation of MAPKKK cascade by fibroblast growth factor receptor signaling pathwayGO:009008010.2FGF23, KL
13positive regulation of bone mineralizationGO:003050110.0KL, PTH
14energy reserve metabolic processGO:000611210.0GNAS, KL
15cellular phosphate ion homeostasisGO:003064310.0FGF23, GCM2, SLC34A1
16fibroblast growth factor receptor signaling pathwayGO:00085439.9FGF23, GALNT3, KL
17response to parathyroid hormoneGO:00711079.8GNAS, PTH, SLC34A1
18ossificationGO:00015039.6CASR, MGP, RUNX2, SLC34A1
19cellular calcium ion homeostasisGO:00068749.6CASR, GCM2, PTH, VDR
20skeletal system developmentGO:00015018.9GNAS, PTH, RUNX2, VDR

Molecular functions related to Hyperphosphatemia according to GeneCards Suite gene sharing:

idNameGO IDScoreTop Affiliating Genes
1fibroblast growth factor receptor bindingGO:00051049.6FGF23, KL

Sources for Hyperphosphatemia

About this section
2CDC
6CNVD
10DGIdb
15ExPASy
16FDA
17FMA
27GTR
28HGMD
29HMDB
30ICD10
31ICD10 via Orphanet
32ICD9CM
33IUPHAR
34KEGG
37MedGen
39MeSH
40MESH via Orphanet
41MGI
44NCI
45NCIt
46NDF-RT
49NINDS
50Novoseek
52OMIM
53OMIM via Orphanet
57PubMed
58QIAGEN
63SNOMED-CT via Orphanet
67Tumor Gene Family of Databases
68UMLS
69UMLS via Orphanet